| 1 |
Determination of a novel antifibrotic small molecule GDC-3280 in human plasma and urine by liquid chromatography tandem mass spectrometry to support its first-in-human clinical trial |
|
|
| Jianshuang Wang,Michael Van Parys,Lin Pan,Yuan Chen,Dorothy Cheung,Janine McKnight,Dennis Milanowski,Xiao Ding,Brian Dean |
|
| Biomedical Chromatography. 2019; 33(4): e4482 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Mechanisms and funding opportunities in genitourinary cancer clinical research |
|
|
| Christopher W. Ryan |
|
| Urologic Oncology: Seminars and Original Investigations. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Pharmaceutical industry contribution to research is essential but full transparency and guidelines are required |
|
|
| Amir Lass |
|
| Human Reproduction. 2017; 32(10): 2147 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data |
|
|
| Oktay Yildirim,Matthias Gottwald,Peter Schüler,Martin C. Michel |
|
| Frontiers in Pharmacology. 2016; 7 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Fellow-Initiated Clinical Trials |
|
|
| Yan Liu,Xuming Dai |
|
| Journal of the American College of Cardiology. 2015; 66(3): 324 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Extension of the primary care research object model (PCROM) as clinical research information model (CRIM) for the “learning healthcare system” |
|
|
| Wolfgang Kuchinke,Töresin Karakoyun,Christian Ohmann,Theodoros N Arvanitis,Adel Taweel,Brendan C Delaney,Stuart M Speedie |
|
| BMC Medical Informatics and Decision Making. 2014; 14(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
